Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session
April 17 2020 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that it will present
information on the edasalonexent program in Phase 3 development for
the treatment of Duchenne muscular dystrophy (DMD) at the 2020
Muscular Dystrophy Association (MDA) Virtual Poster Session later
this month.
During the Virtual Poster Session, Catabasis and collaborators
will present three posters entitled:
- Baseline Characteristics of Patients Enrolled in PolarisDMD, a
Phase 3 Trial of Edasalonexent for Duchenne Muscular Dystrophy.
Richard S. Finkel; Craig McDonald; H. Lee Sweeney; Kathryn Wagner;
Erin Neil; Maria Mancini; James MacDougall; Joanne M. Donovan.
- Edasalonexent Treatment in Young Boys with Duchenne Muscular
Dystrophy is Associated with Age-Normative Growth and Normal
Adrenal Function. Erika L. Finanger; Richard S. Finkel; Gihan I.
Tennekoon; Krista Vandenborne; H. Lee Sweeney; Perry Shieh; Sabrina
W. Yum; Maria Mancini; James MacDougall; Joanne M. Donovan.
- Experience with Edasalonexent Demonstrates Ability of 4 to 7
Year Old Boys with Duchenne Muscular Dystrophy to Take Soft-gel
Capsules in Trials. Maria Mancini; Gigi Shafai; Joanne M. Donovan;
Sachin Chandran; Richard S. Finkel.
The poster session will be available to registered conference
attendees and will be made available under “Our Science” on the
company website at www.catabasis.com.
About Edasalonexent (CAT-1004) Edasalonexent (CAT-1004)
is an investigational oral small molecule designed to inhibit NF-kB
that is being developed as a potential foundational therapy for all
patients affected by DMD, regardless of their underlying mutation.
In DMD the loss of dystrophin leads to chronic activation of NF-kB,
which is a key driver of skeletal and cardiac muscle disease
progression. Our ongoing global Phase 3 PolarisDMD trial is
evaluating the efficacy and safety of edasalonexent for
registration purposes. Edasalonexent is also being dosed in the
GalaxyDMD open-label extension trial. In our MoveDMD Phase 2 trial
and open-label extension, we observed that edasalonexent preserved
muscle function and substantially slowed disease progression
compared to rates of change in a control period, and significantly
improved biomarkers of muscle health and inflammation. The FDA has
granted orphan drug, fast track, and rare pediatric disease
designations and the European Commission has granted orphan
medicinal product designation to edasalonexent for the treatment of
DMD. For a summary of clinical results, please visit
www.catabasis.com.
About Catabasis At Catabasis Pharmaceuticals, our mission
is to bring hope and life-changing therapies to patients and their
families. Our lead program is edasalonexent, an NF-kB inhibitor in
Phase 3 development for the treatment of Duchenne muscular
dystrophy. For more information on edasalonexent and our Phase 3
PolarisDMD trial, please visit www.catabasis.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200417005027/en/
Investor and Media Contact Andrea
Matthews Catabasis Pharmaceuticals, Inc. T: (617) 349-1971
amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Sep 2023 to Sep 2024